LCP-Tacro

Phase 3Small molecule

VVeloxis Pharmaceuticals

LCP-Tacro is one of 88 small molecule programs targeting Liver Transplant. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Kidney TransplantActive, not recruiting

Autoimmune HepatitisActive, not recruiting

Liver TransplantPhase 2

Active, not recruiting

Kidney TransplantPhase 3

Active, not recruiting

Autoimmune HepatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

LCP-Tacro

VVeloxis Pharmaceuticals

Phase 3

4 2

Nulojix

Bristol-Myers Squibb

Preclinical

16 3

Simulect

Novartis

Preclinical

15 4

Medrol

Pfizer

Preclinical

12 5

Zinbryta

Roche

Preclinical

6 6

Zemplar

AbbVie

Preclinical

2 7

Cysteine Hydrochloride

Novartis

Preclinical

1 8

Sensipar

Amgen

Preclinical

1 9

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 10

Radicava

Shionogi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Recruiting

Kidney Transplant

NCT06833463

Clinical

Trials by Indication[1]

Kidney Transplant4 trials

Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients

Recruiting·CChiesi Poland Sp. z o.o.··NCT06833463·120 enrolled

Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant

Completed·VVeloxis Pharmaceuticals·Phase 2·NCT01666951·36 enrolled

Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients

Completed·VVeloxis Pharmaceuticals·Phase 2·NCT00496483·60 enrolled

Show 1 more trial

Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)

Completed·VVeloxis Pharmaceuticals·Phase 3·NCT01438710·44 enrolled

Liver Transplant2 trials

Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients

Completed·VVeloxis Pharmaceuticals·Phase 2·NCT00772148·58 enrolled

Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients

Completed·VVeloxis Pharmaceuticals·Phase 2·NCT00608244·59 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily

Completed·VVeloxis Pharmaceuticals·Phase 3·NCT00817206·326 enrolled

Tacrolimus1 trial

Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

Completed·VVeloxis Pharmaceuticals·Phase 3·NCT01962922·50 enrolled

Autoimmune Hepatitis1 trial

LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis

Terminated·VVeloxis Pharmaceuticals·Phase 2·NCT00608894·13 enrolled

1 more indication

Double-blind1 trial

Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx

Completed·VVeloxis Pharmaceuticals·Phase 3·NCT01187953·543 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for LCP-Tacro. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LCP-Tacro compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LCP-Tacro. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Veloxis Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: VVeloxis Pharmaceuticals

LCP-Tacro

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Kidney Transplant4 trials

Liver Transplant2 trials

Safety and Efficacy1 trial

Tacrolimus1 trial

Autoimmune Hepatitis1 trial

Double-blind1 trial

References

Drug Info

Quick Facts

Related News